Neurocrine Biosciences To Present Multiple New Analyses Of Key Clinical And Patient-Reported Outcomes Up To Two Years Of Treatment With CRENESSITY In Populations With Classic Congenital Adrenal Hyperplasia, At ENDO 2026

뉴스 본문을 불러오고 있어요.

Neurocrine Biosciences To Present Multiple New Analyses Of Key Clinical And Patient-Reported Outcomes Up To Two Years Of Treatment With CRENESSITY In Populations With Classic Congenital Adrenal Hyperplasia, At ENDO 2026 | 웨이프 WAPE

Neurocrine Biosciences To Present Multiple New Analyses Of Key Clinical And Patient-Reported Outcomes Up To Two Years Of Treatment With CRENESSITY In Populations With Classic Congenital Adrenal Hyperplasia, At ENDO 2026

기사 요약

관련 종목

댓글 —